These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12627596)

  • 1. Chronic hepatitis B and hepatocarcinogenesis: does prevention of "collateral damage" bring the cure?
    Manigold T; Rehermann B
    Hepatology; 2003 Mar; 37(3):707-10. PubMed ID: 12627596
    [No Abstract]   [Full Text] [Related]  

  • 2. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage.
    Hsieh YH; Su IJ; Wang HC; Chang WW; Lei HY; Lai MD; Chang WT; Huang W
    Carcinogenesis; 2004 Oct; 25(10):2023-32. PubMed ID: 15180947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatitis B--a viral oncogene?].
    Weis NM; Krogsgaard K
    Ugeskr Laeger; 2002 Dec; 164(50):5940-4. PubMed ID: 12553116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy.
    Nakamoto Y; Kaneko S; Fan H; Momoi T; Tsutsui H; Nakanishi K; Kobayashi K; Suda T
    J Exp Med; 2002 Oct; 196(8):1105-11. PubMed ID: 12391022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice.
    Huang SN; Chisari FV
    Hepatology; 1995 Mar; 21(3):620-6. PubMed ID: 7875658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic hepatitis B].
    Thimme R; Spangenberg HC; Blum HE
    Dtsch Med Wochenschr; 2008 Jan; 133(4):135-8. PubMed ID: 18197589
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma.
    Sitia G; Iannacone M; Guidotti LG
    J Hepatol; 2013 Nov; 59(5):1135-8. PubMed ID: 23742914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma.
    Bonilla Guerrero R; Roberts LR
    J Hepatol; 2005 May; 42(5):760-77. PubMed ID: 15826727
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term high-dose interferon-alpha therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice.
    Merle P; Barraud L; Lefrançois L; Chevallier M; Guerret S; Maisonnas M; Bordes I; Savre-Train I; Trepo C; Vitvitski-Trepo L
    Oncogene; 2003 May; 22(18):2762-71. PubMed ID: 12743599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems.
    Chang MH; Chen TH; Hsu HM; Wu TC; Kong MS; Liang DC; Ni YH; Chen CJ; Chen DS;
    Clin Cancer Res; 2005 Nov; 11(21):7953-7. PubMed ID: 16278421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice.
    Dunsford HA; Sell S; Chisari FV
    Cancer Res; 1990 Jun; 50(11):3400-7. PubMed ID: 1692259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic hepatitis B virus infection and the methylation status of p16INK4A promoter].
    Zhu R; Li BZ; Ling YQ; Zhang HP; Li H; Liu Y; Hu XQ; Zhu HG
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):166-70. PubMed ID: 17649629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the tumor necrosis factor (TNF)--Fas L and HCV in the development of hepatocellular carcinoma.
    Nada O; Abdel-Hamid M; Ismail A; El Shabrawy L; Sidhom KF; El Badawy NM; Ghazal FA; El Daly M; El Kafrawy S; Esmat G; Loffredo CA
    J Clin Virol; 2005 Oct; 34(2):140-6. PubMed ID: 16157266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma.
    El-Bassiouni A; Nosseir M; Zoheiry M; El-Ahwany E; Ghali A; El-Bassiouni N
    APMIS; 2006 Jun; 114(6):420-7. PubMed ID: 16856963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired function of hepatic natural killer cells from murine chronic HBsAg carriers.
    Chen Y; Wei H; Sun R; Tian Z
    Int Immunopharmacol; 2005 Dec; 5(13-14):1839-52. PubMed ID: 16275620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing infection-associated cancer: from bench to hillside.
    Goedert JJ
    J Natl Cancer Inst; 2005 Feb; 97(4):245-6. PubMed ID: 15713953
    [No Abstract]   [Full Text] [Related]  

  • 17. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.
    Lai MW; Yeh CT
    Antivir Ther; 2008; 13(7):875-9. PubMed ID: 19043921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.
    Liaw YF
    Semin Liver Dis; 2005; 25 Suppl 1():40-7. PubMed ID: 16103980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment.
    Sherman M
    Cleve Clin J Med; 2009 May; 76 Suppl 3():S6-9. PubMed ID: 19465708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous in vivo retrovirus-infected T and B cells, but not dendritic cells, mediate antigen-specific Fas ligand/Fas-dependent apoptosis of anti-retroviral CTL.
    Rich RF; Cook WJ; Green WR
    Virology; 2006 Mar; 346(2):287-300. PubMed ID: 16337984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.